ALB and chronic kidney disease: Additionally, Empagliflozin in the Patients with Chronic Kidney Disease (EMPA-Kidney) trial, empagliflozin was given to those with an eGFR of 20 to 45 mL/min/1.73 m2, or an eGFR of at least 45 to 90 mL mL/min/1.73 m2, and a urinary albumin-to-creatinine ratio of at least 200 mg/gCr [10].